Iveric Bio to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Wednesday, March 3, 2021
February 24 2021 - 8:00AM
Business Wire
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will
report its fourth quarter and full year 2020 financial and
operating results on Wednesday, March 3, 2021. Following the
announcement, the Iveric Bio management team will host a live
conference call and webcast at 8:00 a.m. Eastern Time to discuss
the Company’s financial results and provide a general business
update.
To participate in this conference call, dial 888-221-3881 (USA)
or 323-794-2590 (International), passcode 9597743. A live,
listen-only audio webcast of the conference call can be accessed on
the Investors section of the Iveric Bio website at
www.ivericbio.com. A replay will be available approximately two
hours following the live call for two weeks. The replay number is
888-203-1112 (USA Toll Free), passcode 9597743.
About Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused
on the discovery and development of novel treatment options for
retinal diseases with significant unmet medical needs. The Company
is currently developing both therapeutic product candidates for
age-related retinal diseases and gene therapy product candidates
for orphan inherited retinal diseases. Vision is Our Mission. For
more information on the Company, please visit
www.ivericbio.com.
Forward-looking Statements
Any statements in this press release about Iveric Bio’s future
expectations, plans and prospects constitute forward-looking
statements for purposes of the safe harbor provisions under the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors. Any
forward-looking statements represent Iveric Bio’s views only as of
the date of this press release. Iveric Bio anticipates that
subsequent events and developments will cause its views to change.
While Iveric Bio may elect to update these forward-looking
statements at some point in the future, Iveric Bio specifically
disclaims any obligation to do so.
ISEE-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210224005252/en/
Investors: Iveric Bio Kathy Galante, 212-845-8231 Vice
President, Investor Relations and Corporate Communications
kathy.galante@ivericbio.com or Media: SmithSolve Alex Van
Rees, 973-442-1555 ext. 111 alex.vanrees@smithsolve.com
IVERIC bio (NASDAQ:ISEE)
Historical Stock Chart
From Aug 2024 to Sep 2024
IVERIC bio (NASDAQ:ISEE)
Historical Stock Chart
From Sep 2023 to Sep 2024